As of 2026-03-30, the Relative Valuation of Harvard Bioscience Inc (HBIO) is (252.77) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.87 USD, the upside of Harvard Bioscience Inc based on Relative Valuation is -5290.4%.
The range of the Relative Valuation is (226.26) - (284.47) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.5x - 26.0x | 22.7x |
| Forward P/E multiples | 19.3x - 25.8x | 23.2x |
| Fair Price | (226.26) - (284.47) | (252.77) |
| Upside | -4745.9% - -5941.4% | -5290.4% |
| Date | P/E |
| 2026-03-27 | -0.44 |
| 2026-03-26 | -0.46 |
| 2026-03-25 | -0.47 |
| 2026-03-24 | -0.47 |
| 2026-03-23 | -0.48 |
| 2026-03-20 | -0.48 |
| 2026-03-19 | -0.51 |
| 2026-03-18 | -0.44 |
| 2026-03-17 | -0.44 |
| 2026-03-16 | -0.45 |
| 2026-03-13 | -0.43 |
| 2026-03-12 | -0.45 |
| 2026-03-11 | -0.46 |
| 2026-03-10 | -0.48 |
| 2026-03-09 | -0.44 |
| 2026-03-06 | -0.50 |
| 2026-03-05 | -0.52 |
| 2026-03-04 | -0.52 |
| 2026-03-03 | -0.51 |
| 2026-03-02 | -0.54 |
| 2026-02-27 | -0.56 |
| 2026-02-26 | -0.54 |
| 2026-02-25 | -0.55 |
| 2026-02-24 | -0.53 |
| 2026-02-23 | -0.51 |
| 2026-02-20 | -0.53 |
| 2026-02-19 | -0.53 |
| 2026-02-18 | -0.54 |
| 2026-02-17 | -0.54 |
| 2026-02-13 | -0.50 |
| 2026-02-12 | -0.51 |
| 2026-02-11 | -0.49 |
| 2026-02-10 | -0.55 |
| 2026-02-09 | -0.48 |
| 2026-02-06 | -0.45 |
| 2026-02-05 | -0.43 |
| 2026-02-04 | -0.46 |
| 2026-02-03 | -0.45 |
| 2026-02-02 | -0.46 |
| 2026-01-30 | -0.45 |
| 2026-01-29 | -0.49 |
| 2026-01-28 | -0.52 |
| 2026-01-27 | -0.54 |
| 2026-01-26 | -0.52 |
| 2026-01-23 | -0.54 |
| 2026-01-22 | -0.56 |
| 2026-01-21 | -0.54 |
| 2026-01-20 | -0.53 |
| 2026-01-16 | -0.53 |
| 2026-01-15 | -0.53 |